Menu
Global advancements in pharmaceuticals and biotechnology are accelerating like never before. This has led to unprecedented M&A and funding activity as we race to develop medicines, therapies, and devices aimed at improving well-being and confronting health threats, both old and new. Life sciences investment banking requires experienced and nimble financial management.
Our life sciences investment banking team draws on decades of experience coordinating funding, restructuring, M&A execution on behalf of innovative companies in the pharmaceutical and biotech sectors.
Not surprisingly, 2020 saw a record number of biotech industry IPOs raise $13.5 billion.* Quoin provides comprehensive advisory and financing capabilities to support our clients who innovate businesses in the specialty pharmaceutical, generic pharmaceutical and biotechnology sectors, domestically and throughout EMEA and BRIC nations.
Subsector Expertise:
(* Source: BioSpace)
With the increased focus on Environmental, Social and Governance (ESG) criteria, clients can leverage the advice of Quoin’s experienced Sustainability & Renewable Energy team.
